来源：新浪证券-红岸工作室 10月13日，海普瑞跌1.68%，成交额4780.23万元，换手率0.33%，总市值172.26亿元。 异动分析 创新药+生物疫苗+CRO概念+人民币贬值受益 1、2024年年报，海普瑞于 1998 年成立于深圳，是拥有 A+H 双融资平台的领先跨国制药企业，主要业 务覆盖肝素产业链、生物大分子 CDMO 和创新药物的投资、开发及商业化，致力于为全球患者带去高 质量的安全有效药物和服务，护佑健康。 区间今日近3日近5日近10日近20日主力净流入-158.06万279.09万238.61万-1529.18万-5185.99万 主力持仓 主力没有控盘，筹码分布非常分散，主力成交额1053.34万，占总成交额的5.18%。 技术面：筹码平均交易成本为11.57元 2、赛湾生物具备向客户提供mRNA疫苗开发及生产CDMO服务的能力。赛湾生物凭借优秀的工艺开 发、准时交付以及成功的运营能力，继续推进mRNA疫苗供应链的工作，支持全球多个已商业化的 mRNA疫苗的生产。 3、深圳市海普瑞药业集团股份有限公司的主营业务是肝素产业链，生物大分子CDMO和创新药物的投 资，开发及商业化。 4、根据2 ...

FF301 致：香港交易及結算所有限公司 公司名稱: 深圳市海普瑞藥業集團股份有限公司 呈交日期: 2025年10月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09989 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 220,094,500 | RMB | | 1 RMB | | 220,094,500 | | 增加 / 減少 (-) | | | | | | RMB | | | | 本月底結存 | | | 220,094,500 | RMB | | 1 RMB | | 220,094,500 | | 2. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | --- | --- ...

Core Viewpoint - The company, Shenzhen Hepalink Pharmaceutical Group Co., Ltd., is a leading multinational pharmaceutical enterprise with a focus on heparin, biopharmaceutical CDMO, and innovative drug development, benefiting from the depreciation of the RMB and a strong overseas revenue stream [2][3]. Company Overview - Established in 1998 and listed in 2010, Hepalink operates primarily in the heparin industry, with its main business segments including formulations (63.06%), CDMO (18.59%), and heparin raw materials (16.05%) [7]. - As of June 30, 2025, the company reported a revenue of 2.817 billion yuan, a year-on-year decrease of 0.71%, and a net profit of 422 million yuan, down 36.44% year-on-year [7]. Financial Performance - The company’s overseas revenue accounted for 93.04% of total revenue, benefiting from the depreciation of the RMB [3]. - The total market capitalization of Hepalink is 17.666 billion yuan, with a trading volume of 37.9727 million yuan on September 25, 2023 [1]. Shareholder Information - As of June 30, 2025, the number of shareholders decreased by 7.29% to 26,300, with the average circulating shares per person remaining at zero [7]. - The company has distributed a total of 4.21 billion yuan in dividends since its A-share listing, with 514 million yuan distributed over the past three years [8]. Market Activity - On September 25, 2023, the stock price of Hepalink fell by 1.15%, with a turnover rate of 0.25% [1]. - The stock is currently near a resistance level of 12.33 yuan, with an average trading cost of 11.57 yuan [6].

Core Viewpoint - The recent trading activity and financial performance of Haiprui Pharmaceutical indicate a mixed outlook, with notable fluctuations in financing and stockholder dynamics [1][2]. Financing Activity - On September 24, Haiprui's stock rose by 1.16%, with a trading volume of 41.77 million yuan. The financing buy-in amounted to 4.87 million yuan, while the financing repayment was 5.70 million yuan, resulting in a net financing outflow of 0.83 million yuan [1]. - As of September 24, the total financing and securities lending balance for Haiprui was 258 million yuan, with the financing balance of 256 million yuan accounting for 1.69% of the circulating market value, which is above the 60th percentile of the past year [1]. - In terms of securities lending, Haiprui repaid 6,200 shares and sold 8,500 shares on the same day, with a selling amount of 0.1035 million yuan. The remaining securities lending volume was 10,840 shares, with a balance of 1.32 million yuan, exceeding the 90th percentile of the past year [1]. Financial Performance - For the first half of 2025, Haiprui reported a revenue of 2.817 billion yuan, reflecting a year-on-year decrease of 0.71%. The net profit attributable to shareholders was 422 million yuan, down 36.44% year-on-year [2]. - Since its A-share listing, Haiprui has distributed a total of 4.21 billion yuan in dividends, with 514 million yuan distributed over the past three years [2]. Shareholder Dynamics - As of June 30, 2025, Haiprui had 26,300 shareholders, a decrease of 7.29% from the previous period. The average circulating shares per shareholder remained at 0 [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited ranked as the eighth largest, holding 11.32 million shares, an increase of 6.38 million shares from the previous period [2].

Core Viewpoint - The company, Haiprui, is a leading multinational pharmaceutical enterprise with a focus on the heparin industry chain, biopharmaceutical CDMO, and innovative drug development, benefiting from the depreciation of the RMB and a significant overseas revenue share [2][3]. Company Overview - Haiprui was established in 1998 in Shenzhen and has both A and H share financing platforms [2]. - The main business segments include heparin sodium raw materials, downstream low molecular weight heparin products, and CDMO services for biopharmaceuticals [7]. - As of June 30, 2025, Haiprui reported a revenue of 2.817 billion yuan, a year-on-year decrease of 0.71%, and a net profit of 422 million yuan, down 36.44% year-on-year [7]. Financial Performance - The company’s overseas revenue accounted for 93.04% of total revenue, benefiting from the depreciation of the RMB [3]. - The revenue composition includes 63.06% from formulations, 18.59% from CDMO, 16.05% from heparin sodium and low molecular weight heparin raw materials, and 2.30% from other sources [7]. - Cumulative cash dividends since the A-share listing amount to 4.21 billion yuan, with 514 million yuan distributed over the past three years [8]. Market Activity - On September 22, Haiprui's stock price fell by 0.81%, with a trading volume of 45.2628 million yuan and a market capitalization of 18.062 billion yuan [1]. - The stock has seen a net outflow of 3.1095 million yuan from major funds today, indicating a reduction in holdings over the past three days [4][5]. Technical Analysis - The average trading cost of the stock is 11.56 yuan, with the current price approaching a resistance level of 12.33 yuan, suggesting potential for a price correction if this level is not surpassed [6].

Core Viewpoint - The article discusses the performance and business operations of Shenzhen Hepalink Pharmaceutical Group Co., Ltd., highlighting its focus on heparin, biopharmaceuticals, and innovative drugs, as well as the impact of RMB depreciation on its overseas revenue. Company Overview - Shenzhen Hepalink Pharmaceutical Group Co., Ltd. was established in 1998 and is a leading multinational pharmaceutical company with A+H dual financing platforms, primarily engaged in the heparin industry chain, biopharmaceutical CDMO, and innovative drug investment, development, and commercialization [2][7] - The company's main business revenue composition includes: formulations (63.06%), CDMO (18.59%), heparin sodium and low molecular weight heparin raw materials (16.05%), and others (2.30%) [7] Financial Performance - For the first half of 2025, the company achieved operating revenue of 2.817 billion yuan, a year-on-year decrease of 0.71%, and a net profit attributable to shareholders of 422 million yuan, a year-on-year decrease of 36.44% [7] - As of June 30, 2025, the company's overseas revenue accounted for 93.04%, benefiting from the depreciation of the RMB [3] Market Activity - On September 19, the company's stock price fell by 0.72%, with a trading volume of 55.9683 million yuan and a turnover rate of 0.36%, resulting in a total market capitalization of 18.209 billion yuan [1] - The stock has seen a net outflow of 9.4339 million yuan from main funds today, with a continuous three-day reduction in main fund positions [4][5] Technical Analysis - The average trading cost of the stock is 11.56 yuan, with recent chip reduction slowing down; the current stock price is near a resistance level of 12.64 yuan, indicating potential for a pullback if this level is not surpassed [6]

(A joint stock company incorporated in the People's Republic of China with limited liability) （於中華人民共和國註冊成立的股份有限公司） Stock Code 股份代號 : 9989 Interim Report 中期報告 2025 | 管理層討論與分析 | | | --- | --- | | Corporate Governance and Other Information Disclosed | 22 | | 企業管治及其他披露資料 | | | Interim Condensed Consolidated Statements of Profit or Loss | 36 | | 中期簡明綜合損益表 | | | Interim Condensed Consolidated Statements of Comprehensive Income | 37 | | 中期簡明綜合全面收益表 | | | Interim Condensed Consolidated Statements of Financial Posi ...

Core Viewpoint - The article discusses the performance and business operations of Shenzhen Hepalink Pharmaceutical Group Co., Ltd., highlighting its focus on heparin, biopharmaceuticals, and the impact of currency depreciation on its revenue [2][3]. Company Overview - Shenzhen Hepalink Pharmaceutical Group Co., Ltd. was established in 1998 and is a leading multinational pharmaceutical company with A+H dual financing platforms [2]. - The company's main business includes the heparin industry chain, biopharmaceutical CDMO, and the investment, development, and commercialization of innovative drugs [2][7]. - As of June 30, 2025, the company reported a revenue of 2.817 billion yuan, a year-on-year decrease of 0.71%, and a net profit of 422 million yuan, down 36.44% year-on-year [7]. Financial Performance - The company’s overseas revenue accounted for 93.04% of total revenue, benefiting from the depreciation of the Renminbi [3]. - The main business revenue composition includes: formulations (63.06%), CDMO (18.59%), heparin sodium and low molecular weight heparin raw materials (16.05%), and others (2.30%) [7]. - The company has distributed a total of 4.21 billion yuan in dividends since its A-share listing, with 514 million yuan distributed in the last three years [8]. Market Activity - On September 11, the stock price of Hepalink increased by 0.31%, with a trading volume of 75.5743 million yuan and a turnover rate of 0.48%, resulting in a total market capitalization of 18.825 billion yuan [1]. - The stock has seen a net outflow of 5.2287 million yuan from major funds today, with a continuous reduction in major fund positions over the past three days [4][5]. Technical Analysis - The average trading cost of the stock is 11.54 yuan, with the current price near a support level of 12.80 yuan [6].

Group 1 - The Ministry of Industry and Information Technology has officially released the "2025 5G Factory Directory," which includes 560 projects across 48 industries, with Guangdong province contributing 49 projects [1] - Shenzhen has 10 factories listed in the 5G Factory Directory, including notable companies such as Haiprui, Mindray, and BYD, showcasing a diverse range of applications from pharmaceuticals to logistics and transportation [1] - The development of 5G factories is a key task for the large-scale growth of "5G + Industrial Internet," aimed at enhancing efficiency and driving technological innovation in manufacturing [2] Group 2 - Shenzhen has been at the forefront of 5G development, achieving full coverage of 5G infrastructure by 2020 and being selected as one of the first pilot cities for "5G + Industrial Internet" applications in 2024 [3] - The establishment of 5G factories is expected to enhance operational efficiency and reduce costs in the short term, while building competitive advantages and industry influence in the medium term, and providing a gateway to global digital economy participation in the long term [3] - The concentration of 5G factories in Shenzhen reflects its dual commitment to becoming an industrial city and a leader in the digital economy, serving as a core engine for high-quality economic development [3]

Core Viewpoint - The company, Shenzhen Hepalink Pharmaceutical Group Co., Ltd., is a leading multinational pharmaceutical enterprise with a focus on the heparin industry chain, biopharmaceutical CDMO, and innovative drug development, benefiting from the depreciation of the RMB and a strong overseas revenue stream [2][3]. Company Overview - Shenzhen Hepalink was established in 1998 and has dual financing platforms (A+H shares), primarily engaged in the research, production, and sales of heparin sodium raw materials and downstream low molecular weight heparin products [7]. - The company's main business revenue composition includes: formulations (63.06%), CDMO (18.59%), heparin sodium and low molecular weight heparin raw materials (16.05%), and others (2.30%) [7]. Financial Performance - For the first half of 2025, the company reported a revenue of 2.817 billion yuan, a year-on-year decrease of 0.71%, and a net profit attributable to shareholders of 422 million yuan, down 36.44% year-on-year [7]. - The company has distributed a total of 4.21 billion yuan in dividends since its A-share listing, with 514 million yuan distributed over the past three years [8]. Market Position - As of June 30, 2025, the company had a market capitalization of 18.767 billion yuan, with a trading volume of 38.1828 million yuan and a turnover rate of 0.24% [1]. - The company’s overseas revenue accounted for 93.04% of total revenue, benefiting from the depreciation of the RMB [3]. Investment Dynamics - The stock has seen a net outflow of 1.0654 million yuan from major funds today, with a continuous reduction in major fund positions over the past three days [4][5]. - The average trading cost of the stock is 11.53 yuan, with the current price approaching a resistance level of 12.80 yuan, indicating potential for upward movement if the resistance is broken [6].